A method of treating a warm-blooded animal having a proliferative disorder selected from the group consisting of melanoma, lung cancer, colorectal cancer (CRC), breast cancer, kidney cancer, renal cell carcinoma (RCC), liver cancer, myelodysplastic syndromes (MDS), non-small cell lung cancer (NSCLC), thyroid cancer, pancreatic cancer, neurofibromatosis, hepatocellular carcinoma, ovarian cancer, colon cancer, cancer of the gastrointestinal tract, cervix cancer, head and neck cancer, bladder cancer, and Kaposi's sarcoma, comprising administering to said animal (a) a phosphoinositide 3-kinase inhibitor compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine and (b) a compound which modulates Mek kinase activity selected from PD325901, PD-181461, ARRY142886/AZD6244, ARRY-509, XL518, JTP-74057, AS-701255, AS-701173, AZD8330, ARRY162, ARRY300, RDEA436, E6201, RO4987655/R-7167, GSK1120212 or AS703026, wherein the active ingredients are present in free form or in the form of a pharmaceutically acceptable salt thereof, in a quantity which is therapeutically effective against said proliferative disease.